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ABSTRACT
Colonisation of the hepatobiliary system with bile-resistant Helicobacter spp. has been proposed as a
novel risk-factor in the pathogenesis of gall-bladder carcinoma (GBC). There are reports that biliary
Helicobacter colonisation is frequent in countries with a high incidence of gall-bladder carcinoma.
However, the prevalence of Helicobacteraceae in the gall-bladders of patients with GBC in Germany, a
region with a low incidence of GBC, is unknown. Therefore, gall-bladder tissue from 99 patients who
had undergone cholecystectomy was tested, including 57 cases of gall-stone disease (GSD), 20 cases of
GBC, and 22 control patients. The presence of Helicobacter spp. was investigated by culture,
immunohistochemistry and a group-specific PCR targeting the 16S rRNA gene of all currently known
Helicobacteraceae. Of the 99 cases investigated, only one patient with GSD was PCR-positive for
Helicobacteraceae. For this individual, sequence analysis of the 16S rRNA gene showed that it had
homology closest to the 16S rRNA sequence of Helicobacter ganmani. Helicobacteraceae were not detected
by culture or immunohistochemistry. The low prevalence of Helicobacteraceae in the gall-bladders
investigated suggests that Helicobacteraceae do not play a predominant role in the pathogenesis of GSD
and GBC in the German population. The low prevalence could be a possible explanation for a relatively
low incidence of GBC in the German population, despite the fact that GSD, the major risk-factor for
GBC, is highly prevalent.
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INTRODUCTION
Gall-stones are common, affecting c. 25% of
women and 10–15% of men aged >50 years
[1,2]. The prevalence of gall-bladder stones can
reach >60% [1]. In most cases, gall-stones are
asymptomatic; however, although the rate at
which gall-stones become symptomatic is low,
symptomatic gall-stones and associated compli-
cations are a major cause of morbidity in the
western world [1,2]. For example, in the USA,
gall-stone disease (GSD) is the most common
diagnosis for inpatients, with 262 411 hospitalisa-
tions annually and a median inpatient cost of
US$ 11 584 (8900 euros) [1]. Most (c. 70–90%)
cases of gallbladder carcinoma (GBC) are associ-
ated with gall-stones [3], and GSD is the most
important risk-factor for GBC, with a pooled
relative risk of 4.9 [4].
It is assumed that the aetiology of GSD and
GBC is multifactorial; however, the pathogenesis
is not understood fully. In addition to the main
risk-factors (obesity, female gender and age),
there are unidentified genetic and environmental
factors involved in the pathogenesis of gall-stones
and associated GBC that may explain the hetero-
geneous geographical distribution of GSD and
GBC worldwide [3,4]. Infections with bile-resist-
ant Helicobacter spp. have been identified in
patients with biliary tract disorders, and have
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been suspected to trigger stone formation and
tumourigenesis [5]. There seems to be a trend in
regions with a high incidence of GBC, e.g., Chile
and Japan, to have a corresponding high inci-
dence of Helicobacter infections [5–8], while Heli-
cobacter infection occurs more rarely in other
regions with a low incidence of GBC in relation
to the incidence of GSD [9,10].
To test the hypothesis that Helicobacter infection
triggers the development of GBC in regions with a
high incidence of this type of cancer, the presence
of Helicobacter infection was investigated in Ger-
man patients with GSD and GBC in comparison
with controls. Germany is an area with a low
incidence of GBC. In addition, the frequency of
the main established risk-factors was determined
and correlated with Helicobacter infection.
MATERIALS AND METHODS
Subjects
Eighty-four consecutive patients undergoing cholecystectomy
at the Department of General and Abdominal Surgery,
University Hospital of Magdeburg, Germany, between
November 2003 and December 2004, were enrolled in the
study. Exclusion criteria were: (a) a time interval of >20 min
between ligation of the cystic artery during cholecystectomy
and sampling; (b) pre- or intra-operative perforation of the
gall-bladder; and (c) gall-bladder empyaema. In addition,
paraffin-embedded tissues from 15 patients with adenocarci-
noma of the gall-bladder and extra-hepatic biliary tract, who
had undergone cholecystectomy between 1994 and 2005, were
added to the study to increase the limited group of patients
with biliary malignancies. Clinico-pathological data collected
retrospectively included age, gender, body weight, and post-
operative histological diagnosis.
Patients were divided into three groups (GBC, GSD and
controls) when the sample collection had been completed and
a definite clinical and pathological diagnosis was available for
all patients. All patients with a histologically proven malig-
nancy of the gall-bladder were assigned to the GBC group,
regardless of whether they had GSD. Of the remaining
patients, those with gall-stones were assigned to the GSD
group, while all remaining patients were classified as controls.
Assignment to the individual groups was independent of the
indication that led to surgery. For example, patients with
asymptomatic GSD from whom the gall-bladder was removed
during liver resection because of a focal liver lesion were
added to the GSD group, even though the indication for
cholecystectomy was unrelated to GSD. For the patients in the
control group, the cholecystectomy formed part of surgery that
was indicated for reasons other than GSD or GBC (e.g.,
Whipple procedure, liver resection or transplantation, or
trauma).
The study was approved by the local ethics committee, and
informed consent was obtained from all patients included in
the study. The study was conducted according to the Declar-
ation of Helsinki on Guidelines for Biomedical Research.
Body mass index (BMI) was calculated for all patients as
weight (kg) ⁄height squared (m2). Weight was classified by
BMI, according to the US National Obesity Education Initiative
of the National Heart, Lung and Blood Institute [11], as:
underweight, BMI <18.5 kg ⁄m2; normal weight, BMI = 18.5–
24.9 kg ⁄m2; overweight, BMI = 25–29.9 kg ⁄m2; obesity class I,
BMI = 30–34.9 kg ⁄m2; obesity class II, BMI = 35–39.9 kg ⁄m2;
extreme obesity, BMI ‡ 40 kg ⁄m2.
Sample processing
After surgical removal, the gall-bladder was immediately
placed in a sterile dish and transferred to the Department of
Pathology of University Hospital, Magdeburg. Incision,
inspection and tissue preparation were performed under
sterile conditions at room temperature, and were completed
in £15 min. Three mucosa strips were dissected from each
gall-bladder specimen. These included parts of the fundus and
corpus, and measured 5 mm in width and 40–60 mm in length.
Two of these strips were immediately snap-frozen in liquid
nitrogen and stored at )70C for PCR. The third mucosa strip
was transferred in a Portagerm transport tube (bioMe´rieux,
Marcy l’Etoile, France) to the laboratory in which Helicobacter
culture was performed. The period between surgery and the
beginning of culture was generally 2–4 h, but was never >8 h.
Furthermore, two trans-mural longitudinal strips of the gall-
bladder were fixed in formalin and paraffin-embedded for
histological and immunohistological investigation.
Helicobacter pylori culture
Each tissue specimen was plated on a pre-warmed Pylori Agar
plate (bioMe´rieux) and incubated at 37C under microaero-
philic conditions (O2 5%, CO2 10%, N2 85%, v ⁄v). Plates were
inspected after 3, 7 and 14 days, with colonies being charac-
terised further by Gram’s stain and urease, catalase and
oxidase tests to identify Helicobacter spp.
Histochemistry and immunohistochemistry
Paraffin-embedded tissues from all 99 patients were analysed
using haematoxylin and eosin, modified Giemsa and Whar-
tin–Starry stains. For immunohistochemical evaluation of
Helicobacteraceae, 3-lm paraffin-embedded sections were
de-paraffinised and rehydrated, and then subjected to micro-
wave pre-treatment in citrate buffer (0.01 M, pH 6.0;
3 · 10 min at 600 W). Endogenous peroxidase activity was
inhibited with H2O2 3% v ⁄v in phosphate-buffered saline,
pH 7.5, for 15 min. Normal horse serum diluted 1:20 with
phosphate-buffered saline and containing bovine serum albu-
min 1% w ⁄v was incubated with the samples for 20 min to
suppress non-specific binding. Tissue sections were incubated
with polyclonal antibody to H. pylori (Kirkegaard & Perry
Laboratories, Gaithersburg, MD, USA) at a dilution of 1:1500 at
37C for 1 h. According to the manufacturer’s specifications,
this antibody reacts with different H. pylori strains and shows
cross-reactivity to other Helicobacter spp. After being washed in
phosphate-buffered saline, the samples were incubated with a
1:200 dilution of biotinylated anti-goat secondary antibody
(Vector Laboratories, Burlingame, CA, USA) at room tempera-
ture for 30 min. The bound antibody was then detected by the
avidin–biotin complex method (Vectastain Elite ABC Kit;
Vector Laboratories), with 3,3¢-diaminobenzidine 0.1% v ⁄v
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(Sigma-Aldrich, St Louis, MO, USA) as the chromogen. The
specificity of the immunostaining was checked by replacement
of the primary antibody with non-immune serum. Biopsy
samples of H. pylori gastritis served as positive controls. Two
independent observers assessed the immunostaining.
DNA extraction, Helicobacter genus-specific PCR and DNA
sequence analysis
DNA was extracted from frozen gall-bladder tissue using a
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according
to the manufacturer’s recommendations, and from paraffin-
embedded tissue using a NucleoSpin Tissue Kit (Machery-
Nagel, Dueren, Germany). DNA was stored at )20C until use.
Helicobacteraceae were detected using a group-specific PCR
with primers C97-20 (5¢-GGCTATGACGGGTATCCGGC) and
H3A-20 (5¢-GCCGTGCAGCACCTGTTTTC), as described pre-
viously [12]. Positive samples were further analysed using
DNA sequencing to identify the individual Helicobacter spp.
DNA sequencing and subsequent biocomputing were per-
formed as described previously [13,14]. All negative samples
were retested after spiking with 1 pg of H. pylori-derived DNA
in order to rule out the possibility of false-negative results
caused by PCR inhibitors.
Statistical analysis
Incidences of individual risk-factors were analysed using
Fisher’s exact probability test. ANOVA was performed for
comparing BMI and age in the respective patient groups, as
appropriate. For all statistical analyses, significance levels were
set at p £0.05.
RESULTS
All 99 patients included in this study were
analysed for the possible risk-factors for BMI,
female gender, age and Helicobacter status. The
three groups comprised GSD patients (n = 57),
GBC patients (n = 20), and controls without gall-
stones or malignancy of the gall-bladder or the
extra-hepatic bile ducts (n = 22). Gall-stones were
also found in 85% of the patients in the GBC
group.
The mean BMI was 26.8 ± 4.8 kg ⁄m2 in the
GSD group, 27.4 ± 6.0 kg ⁄m2 in the GBC group,
and 24.5 ± 3.7 kg ⁄m2 in the control group. BMI
was significantly higher in the GSD group than in
the controls (p <0.05). The BMI was also higher in
the GBC group than in controls, but the difference
was only marginally significant (p 0.06). There
was no significant difference between the GSD
and GBC groups. Female gender was more
frequent in the GBD (female:male = 1.48) and
GBC (female:male = 1.86) groups than in controls
(female:male = 0.69). There was an increased risk
for GBD and GBC in females (OR 2.24 and 2.68,
respectively), but this finding did not reach
significance (p 0.13 and p 0.12). Patients with
GBC were significantly older than those with
GSD (mean age 68.3 ± 11.2 years vs.
58.2 ± 15.1 years, p <0.01) and controls (mean
age 68.3 ± 11.2 years vs. 53.1 ± 17.3 years,
p <0.005), but the ages of GSD patients and
controls did not differ significantly. These results
are summarised in Table 1.
Three independent methods were used to
investigate gall-bladder tissue for the presence
of Helicobacter spp. Gall-bladder mucosa speci-
mens from 67 patients were cultured on Helicob-
acter-selective agar. Helicobacteracae were not
detected by culture in any of the gall-bladder
samples, but Gram-negative bacteria were
cultured from four samples, and fungi were
present in one case. Immunohistochemistry with
anti-H. pylori antibody was negative for all 99
gall-bladder samples. Gastric mucosa samples col-
onised with H. pylori and ‘Helicobacter heilmannii’
were used as positive controls. The positive
immunoreaction against ‘H. heilmannii’ (Fig. 1)
confirmed the cross-reactivity of the antibody to
other Helicobacter spp.
With use of the group-specific PCR, Helicobacter
DNA was detected in only one sample. The
sensitivity of the PCR assay was <0.1 pg of
Helicobacter DNA (Fig. 2). There was no evidence
of PCR inhibition in the 98 negative samples. In
the positive sample, direct sequencing of 395 bp
of the 764-bp amplicon revealed 100% homology
to the 16S rRNA gene of Helicobacter ganmani [15]
(GenBank AF000221). This patient was a Cauca-
sian male with GSD, aged 65 years, who had
undergone emergency cholecystectomy because of
acute gallbladder disease with biliary colics. Heli-
cobacter was not visible in immunohistochemical
Table 1. Conventional risk-factors for gall-stone disease
and cancer of the gall-bladder and the extra-hepatic bile
ducts, calculated in comparison with control patients
Risk-factor OR (95% CI) p
Gall-stone disease
Age ‡65 years 4.14 (1.15–16.18) 0.01
Overweight (BMI ‡25) 3.05 (1.03–9.23) <0.05
Female gender 2.24 (0.94–1.52) 0.14
Cancer of the gall-bladder and
extra-hepatic bile duct
Age ‡65 years 13.50 (2.54–82.37) <0.001
Overweight (BMI ‡25) 2.10 (0.51–9.58) 0.34
Female gender 2.68 (0.65–11.49) 0.14
BMI, body mass index.
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preparations. Conventional histology showed
chronic active cholecystitis with sub-mucosal
fibrosis.
DISCUSSION
Among the 99 patients investigated in the present
study, there was only one patient in whom
Helicobacter DNA was detected by PCR. Helico-
bacter was not detected by immunohistochemistry
or culture in any of the gall-bladder tissues. Using
different methods, Rudi et al. [9] did not detect
any Helicobacter spp. in the bile of 73 patients with
chronic cholecystitis or occlusion of the common
bile duct. The present study investigated
gall-bladder tissue, which could be of relevance,
as a Brazilian study, investigating both bile and
gall-bladder tissue from the same patients, re-
vealed a positive association between the pres-
ence of H. pylori DNA within the gall-bladder
tissue and cholelithiasis, but no association if the
bile was analysed for H. pylori DNA [16]. Rudi
et al. [9] studied only patients with cholecystitis or
Fig. 1. Immunohistochemical detection of Helicobacteraceae in gastric and gall-bladder mucosa, showing antral mucosa
with (A) Helicobacter pylori and (B) Helicobacter heilmannii. (C) Example of gall-bladder mucosa showing negative results
with the Helicobacter antibody. (D) Gastric antral mucosa as a negative control (Zeiss Axioskop 50 microscope, Nikon
Coolpix 990 camera, original magnification, ·40, ·100).
Fig. 2. Example of the results obtained with the Helico-
bacter pylori group-specific PCR. Lanes: L, 100-bp DNA lad-
der; N, negative control; A, 0.1 pg of Helicobacter DNA; B,
1 pg of Helicobacter DNA; C, 10 pg of Helicobacter DNA; 1–
10, representative patient samples. The sensitivity of the
PCR assay was <0.1 pg of Helicobacter DNA (lane A). The
764-bp PCR product in lane 7 indicates a positive test
result.
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occlusion of the common bile duct. In the present
study, German patients with GBC were also
investigated for the first time. Taken together,
both studies investigated 172 patients from Ger-
many with various diseases of the biliary system.
Only one of 172 patients was PCR-positive for
Helicobacter DNA (<1%). Therefore, it can be
concluded that Helicobacter infection does not
play a significant role in the development of
GSD or GBC in Germany. However, individual
patients may carry entero-hepatic Helicobacter
spp. in the gall-bladder.
H. ganmani was the only Helicobacter sp. detect-
ed in this study. H. ganmani is a novel entero-
hepatic Helicobacter sp. that was first isolated from
the intestines of laboratory mice [15,17,18]. More-
over, H. ganmani has also been detected in liver
biopsy specimens from children with various
chronic liver diseases [19]. The present study is
the second report of the detection of H. ganmani in
human tissue. Thus, H. ganmani appears to be
able to infect both animals and humans, a fact that
may be of zoonotic importance. However, H. gan-
mani seems to be less pathogenic in mice than
other entero-hepatic Helicobacter spp. [20].
Studies conducted in different countries have
found high rates of entero-hepatic Helicobacter
spp. in the biliary tree. It is noteworthy that
countries with a high incidence of bile duct and
gall-bladder cancer, e.g., Chile, Japan and Thai-
land, also have a high prevalence of entero-
hepatic Helicobacter spp. [5–8]. Moreover, in
Japanese and Thai patients, the detection rates
for entero-hepatic Helicobacter spp. were signifi-
cantly higher in patients with biliary tract malig-
nancies than in controls [6]. In other countries
with a relatively low risk of biliary malignancy,
e.g., Germany and The Netherlands, studies have
failed to detect significant numbers of patients
infected with Helicobacter spp. [9,10]. In Germany,
Helicobacter colonisation of the biliary tree appears
to be uncommon [9] (this study), and GBC is a
relatively rare neoplasm, although GSD occurs
frequently. Also, in regions with a high incidence
of GBC, gall-stones are frequent, as are entero-
hepatic Helicobacter spp. Several entero-hepatic
Helicobacter spp. are able to produce cytotoxic
substances [21], and it has been demonstrated that
the level of epithelium proliferation, a condition
that predisposes to carcinogenesis, is higher in
Helicobacter-positive biliary epithelium than in
bacterium-negative epithelium [22]. Therefore,
entero-hepatic Helicobacter spp. are potential can-
didates for increasing the risk of biliary malig-
nancy.
The significance of H. pylori in the biliary tract
is more controversial. Although some studies
have shown a high prevalence of H. pylori in the
biliary system [16,23–28], others have failed to
detect H. pylori [9,10,29]. In the present study,
although all three detection methods were optim-
ised for this organism, H. pylori was not detected.
This agrees with the results of the previous study
carried out in German patients, in which H. pylori
was not detected in the biliary system, although
61% of the patients tested had positive H. pylori
serology [9]. Geographical and regional variations
of hepatobiliary diseases and their aetiologies are
possible explanations for discordant results.
However, methodological problems also have to
be considered [10]. The present study used a PCR
assay that has been evaluated extensively and
used successfully in previous studies [12–14,18].
This PCR assay is able to detect all currently
known Helicobacter and Wolinella spp. [12]. The
sensitivity of the PCR assay was comparable with
that in other studies in which Helicobacter DNA
was detected frequently [5,7]. However, false-
negative results caused by PCR inhibitors were
excluded by retesting spiked samples, although
the amount of spiked DNA used may not have
been able to detect low-level inhibition. The
immunohistochemical approach has also been
tested extensively, and the H. pylori culture
method is well-established, with a positive cul-
ture rate of >90% in mucosal biopsy specimens
obtained from H. pylori-positive gastritis patients.
However, the culture approach is optimised for
H. pylori and may not be optimal for other
Helicobacter spp. because of the absence of hydro-
gen in the gas mixture.
In addition to the Helicobacter status of individ-
ual patients, other major established risk-factors
for GSD, i.e., obesity, female gender and age, were
also investigated. The most significant risk-factors
for gall-stone disease were an age ‡65 years and
being overweight (Table 1). Female gender also
had an increased OR, but was not statistically
significant. In the cancer group, an age ‡65 years
was a strong risk-factor, with an OR of 13.5.
Moreover, patients with GBC were significantly
older than patients with GSD, while there was no
significant difference between the groups with
respect to BMI and gender. It is noteworthy that
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85% of the patients in the GBC group also had
gall-stones.
Taken together, the results of this study sup-
port the concept that being overweight and
female are causative risk-factors for the formation
of gall-stones and the subsequent development of
malignancy. Infection of the biliary tree and the
gall-bladder with entero-hepatic Helicobacter spp.
is likely to be an additional important risk-factor
that functions as a mechanism triggering malig-
nancy in gall-stone formation and in its later
complications. Therefore, regional differences in
the incidence of Helicobacter infections could
explain the high incidence of GBC in various
countries.
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